Skip to main content

Edwards Lifesciences Corp Value Stock - Dividend - Research Selection

Edwards lifesciences

ISIN: US28176E1082 , WKN: 936853

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic heart valves and related delivery systems for the nonsurgical replacement of heart valves. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings and the beating-heart mitral repair systems; and cardiac cannula devices, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient\'s heart function in surgical and intensive care settings; pulmonary artery catheters; Oximetry Central Venous catheters, as well as clinical monitoring platforms that display a patient\'s physiological status; and disposable pressure monitoring devices and closed blood sampling systems to protect patients and clinicians from infection. The company distributes its products through direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1999 and is headquartered in Irvine, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Institutional investors in Edwards Lifesciences Corporation (NYSE:EW) see US$1.5b decrease in market cap last week, although long-term gains have benefitted them.

2025-09-15
Key Insights Given the large stake in the stock by institutions, Edwards Lifesciences' stock price might be vulnerable...

Undervalued Small Caps With Insider Buying In Global For September 2025

2025-09-15
As global markets navigate the anticipation of a Federal Reserve rate cut and the excitement surrounding artificial intelligence advancements, small-cap stocks have shown resilience, with the Russell 2000 Index marking its sixth consecutive week of gains. In this environment of shifting economic indicators and market sentiment, identifying promising small-cap opportunities often involves looking at those with strong fundamentals and insider confidence, as these factors can indicate potential...

Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day

2025-09-10
Edwards Lifesciences Corp. stock outperforms competitors despite losses on the day

Picard Announces Appointment of Two New Members to its Board of Directors

2025-09-10
Appointments strengthen Picard’s Board with proven expertise in capital markets and global MedTech leadershipTUCSON, Ariz., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American: PMI) (“Picard” or the “Company”), parent company of SynCardia Systems LLC, maker of the world’s first U.S. and Canadian commercially-approved total artificial heart, today announced the appointment of two new members that will serve on its Board of Directors, Sam Van and George Ye. Both were appointed f

Edwards Lifesciences Corporation (EW) Welcomes Newly Updated ESC/EACTS Guidelines for Severe Aortic Stenosis (AS)

2025-09-10
Edwards Lifesciences Corporation (NYSE:EW) is one of the 14 Tech Stocks to Sell Now According to Ken Fisher. In an announcement on August 29, 2025, Edwards Lifesciences Corporation (NYSE:EW) expressed its positive response to newly updated ESC/EACTS guidelines for severe aortic stenosis (AS), which recommend earlier treatment, including for asymptomatic patients, and lower the TAVR […]

Edwards Lifesciences’ TAVR growth continues as global demand rises

2025-09-05
The company holds more than 60% of the global TAVR market share and 75% in the US.

Top Stock Reports for Apple, Novartis & Charles Schwab

2025-09-04
Apple grows Services to 1B+ paid subscribers, while Novartis lifts guidance and Schwab rides higher rates to asset gains.

Edwards, Medtronic and Abbott stand to benefit from new TAVR guidelines in Europe

2025-09-03
Analysts said the companies should benefit “as the therapy algorithm is further streamlined and additional patients are encouraged to receive TAVR.”

Leerink Partners Lifts Edwards Lifesciences (EW) Price Target Amid Buybacks Focus

2025-09-02
Edwards Lifesciences Corporation (NYSE:EW) is one of the top stock picks in Ken Griffin’s portfolio. On August 20, analysts at Leerink Partners reiterated a ‘Market Perform’ rating and hiked the stock’s price target to $85 from $84. The price target hike comes as the stock outperforms the overall market, rallying by 11% year to date. […]

Edwards Lifesciences Stock: Is EW Outperforming the Healthcare Sector?

2025-09-02
As Edwards Lifesciences outshines the broader healthcare sector, Wall Street remains optimistic about its prospects.